{"result": {"id": "a57b7239-d98d-49a2-b43b-ba310c95f3e7", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI is a type of antihypertensive drug widely used for patients with LVH, chronic heart failure, chronic coronary heart disease, myocardial infarction, CKD, and proteinuria)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB is an alternative to ACEI for patients who cannot tolerate ACEI due to side effects like dry cough)\n##\n(\"entity\"<|>CKD<|>ORGANIZATION<|>Chronic Kidney Disease (CKD) is a condition where patients may experience elevated blood potassium levels when using ACEI or ARB)\n##\n(\"entity\"<|>LVH<|>ORGANIZATION<|>Left Ventricular Hypertrophy (LVH) is a condition where ACEI is particularly effective)\n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium Channel Blockers (CCB) are a class of antihypertensive drugs including Dihydropyridine and Non-dihydropyridine types)\n##\n(\"entity\"<|>NIFEDIPINE<|>ORGANIZATION<|>Nifedipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>AMLODIPINE<|>ORGANIZATION<|>Amlodipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>FELODIPINE<|>ORGANIZATION<|>Felodipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>LACIDIPINE<|>ORGANIZATION<|>Lacidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>NICARDIPINE<|>ORGANIZATION<|>Nicardipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>NITRENDIPINE<|>ORGANIZATION<|>Nitrendipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>BENIDIPINE<|>ORGANIZATION<|>Benidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>LERCANIDIPINE<|>ORGANIZATION<|>Lercanidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>MANIDIPINE<|>ORGANIZATION<|>Manidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>CILNIDIPINE<|>ORGANIZATION<|>Cilnidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>BARNIDIPINE<|>ORGANIZATION<|>Barnidipine is a Dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>VERAPAMIL<|>ORGANIZATION<|>Verapamil is a Non-dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>DILTIAZEM<|>ORGANIZATION<|>Diltiazem is a Non-dihydropyridine CCB used for hypertension treatment)\n##\n(\"entity\"<|>CAPTOPRIL<|>ORGANIZATION<|>Captopril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>ENALAPRIL<|>ORGANIZATION<|>Enalapril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>BENAZEPRIL<|>ORGANIZATION<|>Benazepril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>LISINOPRIL<|>ORGANIZATION<|>Lisinopril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>RAMIPRIL<|>ORGANIZATION<|>Ramipril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>FOSINOPRIL<|>ORGANIZATION<|>Fosinopril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>CILAZAPRIL<|>ORGANIZATION<|>Cilazapril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>PERINDOPRIL<|>ORGANIZATION<|>Perindopril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>IMIDAPRIL<|>ORGANIZATION<|>Imidapril is an ACEI used for hypertension treatment)\n##\n(\"entity\"<|>LOSARTAN<|>ORGANIZATION<|>Losartan is an ARB used for hypertension treatment)\n##\n(\"entity\"<|>VALSARTAN<|>ORGANIZATION<|>Valsartan is an ARB used for hypertension treatment)\n##\n(\"entity\"<|>IRBESARTAN<|>ORGANIZATION<|>Irbesartan is an ARB used for hypertension treatment)\n##\n(\"entity\"<|>TELMISARTAN<|>ORGANIZATION<|>Telmisartan is an ARB used for hypertension treatment)\n##\n(\"entity\"<|>CANDESARTAN<|>ORGANIZATION<|>Candesartan is an ARB used for hypertension treatment)\n##\n(\"entity\"<|>OLMESARTAN<|>ORGANIZATION<|>Olmesartan is an ARB used for hypertension treatment)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>ARB is an alternative to ACEI for patients who cannot tolerate ACEI due to side effects like dry cough<|>7)\n##\n(\"relationship\"<|>ACEI<|>CKD<|>ACEI is used for patients with CKD but may cause elevated blood potassium levels<|>6)\n##\n(\"relationship\"<|>ARB<|>CKD<|>ARB is used for patients with CKD but may cause elevated blood potassium levels<|>6)\n##\n(\"relationship\"<|>ACEI<|>LVH<|>ACEI is particularly effective for patients with LVH<|>8)\n##\n(\"relationship\"<|>CCB<|>NIFEDIPINE<|>Nifedipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>AMLODIPINE<|>Amlodipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>FELODIPINE<|>Felodipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>LACIDIPINE<|>Lacidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>NICARDIPINE<|>Nicardipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>NITRENDIPINE<|>Nitrendipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>BENIDIPINE<|>Benidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>LERCANIDIPINE<|>Lercanidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>MANIDIPINE<|>Manidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>CILNIDIPINE<|>Cilnidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>BARNIDIPINE<|>Barnidipine is a type of Dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>VERAPAMIL<|>Verapamil is a type of Non-dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>CCB<|>DILTIAZEM<|>Diltiazem is a type of Non-dihydropyridine CCB<|>9)\n##\n(\"relationship\"<|>ACEI<|>CAPTOPRIL<|>Captopril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>ENALAPRIL<|>Enalapril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>BENAZEPRIL<|>Benazepril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>LISINOPRIL<|>Lisinopril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>RAMIPRIL<|>Ramipril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>FOSINOPRIL<|>Fosinopril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>CILAZAPRIL<|>Cilazapril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>PERINDOPRIL<|>Perindopril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ACEI<|>IMIDAPRIL<|>Imidapril is a type of ACEI<|>9)\n##\n(\"relationship\"<|>ARB<|>LOSARTAN<|>Losartan is a type of ARB<|>9)\n##\n(\"relationship\"<|>ARB<|>VALSARTAN<|>Valsartan is a type of ARB<|>9)\n##\n(\"relationship\"<|>ARB<|>IRBESARTAN<|>Irbesartan is a type of ARB<|>9)\n##\n(\"relationship\"<|>ARB<|>TELMISARTAN<|>Telmisartan is a type of ARB<|>9)\n##\n(\"relationship\"<|>ARB<|>CANDESARTAN<|>Candesartan is a type of ARB<|>9)\n##\n(\"relationship\"<|>ARB<|>OLMESARTAN<|>Olmesartan is a type of ARB<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558615, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2443, "prompt_tokens": 2636, "total_tokens": 5079, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 844}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 用[250]  ,是适应证最为  广泛的降压药 。ACEI尤其适用于伴 LVH、慢性心力  衰竭、慢性冠心病、心肌梗死后心功能不全、CKD、蛋  白尿患者[249-251] 。利尿剂与 ACEI合用有助于缺血性\n\n\n\n脑卒中的二级预防[252] 。\n　　最常见不良反应为干咳 ,多见于用药初期 ,症状较 轻者可坚持服药 ,不能耐受者可改用 ARB。其他不良 反应有低血压、皮疹 。 由 ACEI引起的潜在危及生命\n\n\n　的血管性水肿的发生率<1% ,在中国更低[253] 。偶见 味觉障碍 。CKD患者长期应用 ACEI或 ARB有可能 导致血钾升高 ,应定期监测血钾和血肌酐水平 。禁忌 证为双侧肾动脉重度狭窄、高钾血症及妊娠妇女。\n\n\n表 15   常用的各种降压药\n\n口服降压药\t消除半衰期 (h)\t剂量(起始剂量~足量)\n(mg/d)\t每天服药 次数\t主要不良反应\n二氢吡啶类 CCB 硝苯地平\n硝苯地平缓释片 硝苯地平控释片 氨氯地平\n左氨氯地平 非洛地平\n非洛地平缓释片\n拉西地平 尼卡地平 尼群地平 贝尼地平 乐卡地平 马尼地平 西尼地平 巴尼地平\t\n5\n\t\n\t\n30~50 35~50 10~25\n-\n　13~19 8. 6\n10~22 1~2   8~10\n　5~7 5. 2\n9. 4~11\t\n　10~30 20~40\n　30~60 2. 5~10 2. 5~5   2. 5~10 2. 5~10\n2~8\n40~80\n20~60\n2~8\n10~20\n　5~20 5~10 10~15\t\n2~3 2 1 1 1 2 1 1\n2\n2~3 1 1 1 1 1\t踝部水肿 ,头痛 ,潮红\n非二氢吡啶类 CCB\t\t\t\t房室传导阻滞 ,心功能抑制\n维拉帕米\t3~7\t　　　\t2~3\t\n维拉帕米缓释片\t-\t　　　\t1~2\t\n地尔硫片\t3~5\t　　　\t3\t\n地尔硫缓释胶囊\t5~7\t　　　\t1~2\t\nACEI\n　卡托普利 依那普利 贝那普利 赖诺普利 雷米普利 福辛普利 西拉普利 培哚普利 咪哒普利\t\n　　3 \t\t11 \t22 12. 6\n　13~17 11. 5\n9\n30~120 8\t\n　25~300 2. 5~40\n　　5~40 2. 5~40 1. 25~20\n　10~40 1. 25~5\n　2~8  2. 5~10\t\n2~3 2\n1~2 1 1 1 1 1 1\t咳嗽 ,血钾升高 ,血管神经性水肿\nARB\t\t\t\t血钾升高 ,血管性神经水肿(罕见)\n氯沙坦钾\t6~9\t　　　\t1\t\n缬沙坦\t9\t　　　\t1\t\n厄贝沙坦\t11~15\t　　　\t1\t\n替米沙坦\t24\t　　　\t1\t\n坎地沙坦酯\t9. 5~11. 2\t　　　\t1\t\n奥美沙坦酯\t13\t　　　\t1\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_6a498344eddcf49396d286e8f5839f463fabf148b3451409ea816d9574bba8f0_v2"}